Moreover, the utilization of ENTPD3 as an independent biomarker for CRC immunotherapy needs to be prospectively evaluated in large-sample, multicenter clinical cohorts, especially across different subgroups such as MSS CRC. Here, ENTPD3 is linked to colorectal carcinoma.